NASDAQ: LEGNLegend Biotech Corp Stock
$33.38-2.10 (-5.92%)
Updated Jun 16, 2026
LEGN Price
$33.38
Fair Value Price
N/A
Market Cap
$6.20B
52 Week Low
$16.24
52 Week High
$45.30
P/E
-24.54x
P/B
6.41x
P/S
2.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.14B
Earnings
-$250.27M
Gross Margin
55%
Operating Margin
-18.86%
Profit Margin
-22%
Debt to Equity
0.65
Operating Cash Flow
-$79M
Beta
0.76
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LEGN Overview
Legend Biotech Corporation is a clinical-stage biopharmaceutical firm, operating through its various subsidiaries, dedicated to the discovery and advancement of innovative cell therapies. These treatments primarily target oncological conditions but also address other diseases across the United States, China, and international markets. The company's most advanced investigational therapy is LCAR-B38M, a chimeric antigen receptor (CAR) product specifically developed for treating multiple myeloma (MM). This lead candidate is currently undergoing comparative evaluation against standard triplet therapies in patients suffering from revlimid-refractory multiple myeloma. Additionally, Legend Biotech possesses a pipeline of early-stage, autologous product candidates, which are presently in Phase I clinical trials for addressing gastric cancer and T-cell lymphoma. The company is also actively developing CAR-T cell therapies designed to target CD20, CD22, and CD19 for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further expanding its therapeutic scope, the firm has product candidates in both early preclinical and clinical development phases aimed at solid tumors and infectious diseases. A significant collaboration exists with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel. Founded in 2014, Legend Biotech Corporation is based in Somerset, New Jersey, and functions as a subsidiary of Genscript Biotech Corporation.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LEGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LEGN
Ranked#77 of 462
Ranked#77 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important LEGN news, forecast changes, insider trades & much more!
LEGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LEGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LEGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LEGN is poor value based on its book value relative to its share price (6.41x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
LEGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LEGN due diligence checks available for Premium users.
Valuation
LEGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.54x
Industry
16.03x
Market
13.25x
LEGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.41x
Industry
4.86x
LEGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LEGN's financial health
Profit margin
Revenue
$305.1M
Net Income
-$54.3M
Profit Margin
-17.8%
LEGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LEGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$629.0M
Debt to equity
0.65
LEGN's short-term assets ($1.08B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEGN's short-term assets ($1.08B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LEGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$85.1M
Investing
-$168.0M
Financing
-$1.2M
LEGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LEGN vs Biotech Stocks
Legend Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.